The Bottom Line
We have an elegantly simple solution that prevents retained guidewires, a Joint Commission Never Event that costs the healthcare system ~$893M annually.Our patented solution has physician endorsement for its efficacy and integration into current workflows, a straightforward FDA path, and a market validated by CMS data.Our time to revenue (2 years) is quick, and so is time to exit. We are positioned as an ideal M&A tuck-in target that can incrementally unlock the $1.3B CVC market and provide early revenue of ~$247M.This is not a 15-year, low-probability, $1B TAVI. What it is, is a simple solution and a quick win.
Core Team
We have an all-star team of clinicians, engineers, strategists, operators, and consultants making this work a reality
Rhodel Dacanay
Founder, CEO, and Private Practice AnesthesiologistExperience:
- US Naval Academy
- ASMG Private Practice and Quality Committee
- Barrow Neurological Institute
- BNI Innovation Committee
Betty Tsai
Health Economics, GTM, and Reimbursement StrategyExperience:
- MedTech Innovator
- Boston Scientific
- Siemens Healthineers
- Cardiology Services International
Expanded Team
Selected team members, consultants, and advisors
Ralph Dengler
Legal and Intellectual PropertyExperience:
- Venable LLP
- US Naval Academy
Stephen Murray
Engineering - Manages contract engineering resourcesExperience:
- Arrotek
- VistaMed
Arun Radhakrishnan
Strategy and OperationsExperience:
- TPG Inc.
- Ares Capital Corportation
- NYU Langone Health
Khirin Dacanay
Strategy and OperationsExperience:
- KPMG Deal Advisory and Strategy
- Northrop Grumman Finance
- UA MIS and Accounting (4.0/4.0)
- Harvard Business School SVMP
The Opportunity
The ASA closed claims database lists guidewire retention/injury as the leading cause of catheter-related indemnity payouts. This medical error has a 15.5% mortality and serious morbidity rate, is a Joint Commission "Never Event," and it affects CMS quality scores and reimbursements. This adds up to an approximately $900M annual burden on the US healthcare system.Nevent’s patented Safety Sheath engineers out this human error with a solution that is intuitive to use, completely effective, and fits seamlessly into current workflows as verified by physician testing. Additionally, it is simple and inexpensive to manufacture, with a straightforward 510K regulatory pathway, and eager early adopters identified through the CMS quality reports and the medical literature. Connections with target hospital systems and KOLs are already in place.With those eager adopters, Nevent can achieve early revenue of $100M to $300M within 3-4 years, positioning us as an ideal M&A tuck-in target as we incrementally unlock this $1.3B annual market. This is not a 15-year long, low probability, $1B TAVI. What it is, is a simple solution and a quick win with a verified market that will set a new standard of care in the placement of vascular catheters.
Inquiries
Nevent is actively seeking partners and companies interested in our technologies. Whether you are an investor, medical company, or another interested party, we would love to get in touch!Please reach out to our primary contact, Dr. Rhodel Dacanay, at (858) 231-3162 or [email protected]You may also reach out to Khirin Dacanay at (858) 249-9989 or [email protected]
Contact
Please see below
ContactPrimary:
[email protected]
+1 (858) 231-3162Secondary:
[email protected]
+1 (858) 249-9989
NEVENTAZ LLC10125 S 38th Ln., Phoenix, AZ 85339
Nevent Inc.
DBA Dacanay Ventures Inc.